KR20240015093A - Fc 수용체에 대한 향상된 친화성 및 개선된 열 안정성을 갖는 Fc 변이체 - Google Patents

Fc 수용체에 대한 향상된 친화성 및 개선된 열 안정성을 갖는 Fc 변이체 Download PDF

Info

Publication number
KR20240015093A
KR20240015093A KR1020237044602A KR20237044602A KR20240015093A KR 20240015093 A KR20240015093 A KR 20240015093A KR 1020237044602 A KR1020237044602 A KR 1020237044602A KR 20237044602 A KR20237044602 A KR 20237044602A KR 20240015093 A KR20240015093 A KR 20240015093A
Authority
KR
South Korea
Prior art keywords
amino acid
domain
acid position
polypeptide
effector
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237044602A
Other languages
English (en)
Korean (ko)
Inventor
요헨 베닝가
베아트리체 카메론
잉고 포켄
사가르 카투리아
크리스티안 랑게
알레산드로 마시에로
성해 박
보도 틸만
Original Assignee
사노피
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 사노피 filed Critical 사노피
Publication of KR20240015093A publication Critical patent/KR20240015093A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
KR1020237044602A 2021-05-27 2022-05-27 Fc 수용체에 대한 향상된 친화성 및 개선된 열 안정성을 갖는 Fc 변이체 Pending KR20240015093A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163193665P 2021-05-27 2021-05-27
US63/193,665 2021-05-27
EP21315127 2021-07-15
EP21315127.7 2021-07-15
PCT/IB2022/055019 WO2022249146A1 (en) 2021-05-27 2022-05-27 Fc VARIANT WITH ENHANCED AFFINITY TO Fc RECEPTORS AND IMPROVED THERMAL STABILITY

Publications (1)

Publication Number Publication Date
KR20240015093A true KR20240015093A (ko) 2024-02-02

Family

ID=82358573

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237044602A Pending KR20240015093A (ko) 2021-05-27 2022-05-27 Fc 수용체에 대한 향상된 친화성 및 개선된 열 안정성을 갖는 Fc 변이체

Country Status (12)

Country Link
US (2) US12297273B2 (https=)
EP (1) EP4347640A1 (https=)
JP (1) JP2024522092A (https=)
KR (1) KR20240015093A (https=)
AU (1) AU2022282666A1 (https=)
BR (1) BR112023022584A2 (https=)
CA (1) CA3216005A1 (https=)
CO (1) CO2023016432A2 (https=)
IL (1) IL308733A (https=)
MX (1) MX2023014100A (https=)
TW (1) TW202306584A (https=)
WO (1) WO2022249146A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12286475B2 (en) 2023-07-31 2025-04-29 Sanofi Anti-GPRC5D antibodies and compositions

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0627932B1 (en) 1992-11-04 2002-05-08 City Of Hope Antibody construct
BR9606706A (pt) 1995-10-16 1999-04-06 Unilever Nv Análogo de fragmento de anticorpo biespecífico ou bivalente uso processo para produzir o mesmo
GB9524973D0 (en) 1995-12-06 1996-02-07 Lynxvale Ltd Viral vectors
CA2410551A1 (en) 2000-06-30 2002-01-10 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw (Vib) Heterodimeric fusion proteins
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
US7312181B2 (en) 2005-04-08 2007-12-25 Cropsolution, Inc. Acylated thiosemicarbazides as herbicides
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
JP5898082B2 (ja) * 2009-10-07 2016-04-06 マクロジェニクス，インコーポレーテッド フコシル化程度の変更により改良されたエフェクター機能を示すＦｃ領域含有ポリペプチドおよびその使用法
TWI743461B (zh) 2011-03-28 2021-10-21 法商賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
EP2825557B1 (en) * 2012-03-16 2017-06-28 The U.S.A. as represented by the Secretary, Department of Health and Human Services Soluble engineered monomeric fc
US10011660B2 (en) 2012-04-30 2018-07-03 Medimmune, Llc Molecules with reduced effector function and extended half-lives, compositions, and uses thereof
ES2876009T3 (es) 2012-12-27 2021-11-11 Chugai Pharmaceutical Co Ltd Polipéptido heterodimerizado
US9580486B2 (en) 2013-03-14 2017-02-28 Amgen Inc. Interleukin-2 muteins for the expansion of T-regulatory cells
CN120988137A (zh) 2015-01-23 2025-11-21 赛诺菲 抗cd3抗体、抗cd123抗体和与cd3和/或cd123特异性结合的双特异性抗体
EA201891753A1 (ru) * 2016-02-03 2019-01-31 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкции антител к psma и cd3, вовлекающие т-клетки
CA3020633A1 (en) 2016-04-13 2017-10-19 Sanofi Trispecific and/or trivalent binding proteins
AR108963A1 (es) 2016-04-13 2018-10-17 Merial Inc Dispositivo de inyección con mecanismo de accionamiento para administrar múltiples formulaciones líquidas, tales como vacunas
CN108218998A (zh) * 2017-12-31 2018-06-29 武汉班科生物技术股份有限公司 一种突变型人源IgG的Fc片段及其制备方法与应用
IL276286B2 (en) 2018-01-26 2025-07-01 Genzyme Corp FC variants with improved binding to FCRN and extended half-life
WO2019185164A1 (en) 2018-03-29 2019-10-03 Hummingbird Bioscience Holdings Pte. Ltd. Her3 antigen-binding molecules
JP7792330B2 (ja) * 2019-09-03 2025-12-25 アムジエン・インコーポレーテツド Ｉｌ－２２の経口、直腸内、又は他の消化管関連の組成物及びそれを使用する方法

Also Published As

Publication number Publication date
AU2022282666A1 (en) 2024-01-18
IL308733A (en) 2024-01-01
CA3216005A1 (en) 2022-12-01
BR112023022584A2 (pt) 2024-01-09
CO2023016432A2 (es) 2023-12-11
US20230077531A1 (en) 2023-03-16
MX2023014100A (es) 2023-12-11
US20250376526A1 (en) 2025-12-11
TW202306584A (zh) 2023-02-16
US12297273B2 (en) 2025-05-13
WO2022249146A1 (en) 2022-12-01
JP2024522092A (ja) 2024-06-11
EP4347640A1 (en) 2024-04-10

Similar Documents

Publication Publication Date Title
JP7178342B2 (ja) アゴニズム及びエフェクター機能が増強した改変抗体、及び他のＦｃドメイン含有分子
RU2729467C2 (ru) Модифицированные антигенсвязывающие полипептидные конструкции и их применение
EP2970435B1 (en) Methods for producing fabs and bi-specific antibodies
WO2011084714A2 (en) STABILIZED ANTI-TNF-ALPHA scFv MOLECULES OR ANTI-TWEAK scFv MOLECULES AND USES THEREOF
JP2020202848A (ja) 修飾された抗原結合ポリペプチド構築物及びその使用
KR20240161977A (ko) 항-CD28 x 항-PSMA 항체
EP4155318A1 (en) Bispecific antibody and use thereof
JP2023548109A (ja) デルタガンマ鎖媒介性免疫を調節するための組成物及び方法
US20250376526A1 (en) Fc VARIANT WITH ENHANCED AFFINITY TO Fc RECEPTORS AND IMPROVED THERMAL STABILITY
JP2025542239A (ja) 自己免疫疾患の治療
AU2020358898B2 (en) Hybrid antibody
KR101744899B1 (ko) 신규 항-tfpi 항체 및 이를 포함하는 조성물
CN117377685A (zh) 具有对Fc受体的增强的亲和力和改善的热稳定性的Fc变体
US20250206824A1 (en) GLYCOENGINEERED Fc VARIANT POLYPEPTIDES WITH ENHANCED EFFECTOR FUNCTION
US20240360233A1 (en) Anti-tslpr (crlf2) antibodies
WO2024153068A1 (en) Anti-pdl1 single domain antibody, fusion protein and use thereof
WO2025088546A1 (en) Fc domain variants with enhanced fc receptor binding
KR20250024825A (ko) 폴리스타틴-fc 융합 단백질
RU2832921C1 (ru) Модифицированные антигенсвязывающие полипептидные конструкции и их применение
CN120641441A (zh) 抗cd3抗体

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20231222

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20250526

Comment text: Request for Examination of Application